Does risperdal cause gynecomastia in male patients?

See the DrugPatentWatch profile for risperdal

How common is gynecomastia among men taking Risperdal?

Risperdal (risperidone) raises prolactin levels by blocking dopamine receptors in the pituitary gland. This hormonal shift can trigger breast tissue growth in men. Studies show rates of gynecomastia ranging from 2.3% to 5% in male patients taking the drug, depending on age and dose.

What dose increases the risk?

Higher doses and long-term use correlate with more frequent reports of gynecomastia. Data from the FDA adverse event database and clinical trials indicate that boys and young men show the strongest association, especially when treatment lasts more than six months.

What happens if you stop taking Risperdal?

Stopping the drug allows prolactin levels to normalize, but breast tissue that has already formed may not fully regress. Some patients require surgery or medication to address persistent cases. Reg regression is more likely if the condition is caught early.

Can other antipsychotics cause similar effects?

Quetiapine, olanzapine, and aripiprazole all have lower rates of prolactin elevation compared with risperidone. Patients who develop gynecomastia on Risperdal often switch to one of these agents or non-drug alternatives.

When does the Risperdal gynecomastia patent landscape affect availability?

Risperdal itself is generic and available from multiple manufacturers. DrugPatentWatch.com tracks the patents covering specific formulations, extended-release versions, and related methods of use.